The accepted abstract, titled “Disrupting the Oncobiosphere: CAF-Targeting Therapy with Penetrium Reverses Pseudo-Resistance in Tumors,” introduces a groundbreaking perspective on chemotherapy failure. It shifts the focus from traditional genetic resistance to structural barriers within the tumor microenvironment, a concept that has garnered significant attention from the global oncology community.
The research highlights the role of cancer-associated fibroblasts (CAFs) and the pathological extracellular matrix (ECM) as primary impediments to the efficacy of existing anticancer drugs. Penetrium, a nanohybrid drug derived from niclosamide, selectively dismantles these barriers, restoring the effectiveness of conventional chemotherapies without harming normal fibroblasts. This approach, termed “structural therapy,” represents a novel paradigm in cancer treatment.
The concept of “pseudo-resistance,” pioneered by Hyundai ADM Bio and Hyundai BioScience, redefines chemotherapy failure as a consequence of the tumor microenvironment’s structural defenses rather than solely genetic mutations. The acceptance of this abstract elevates pseudo-resistance from a corporate hypothesis to a global scientific agenda, drawing attention from leading cancer researchers worldwide.
Won-Dong Cho, CEO of Hyundai ADM Bio, underscored the milestone’s implications. “This acceptance marks a turning point for treating metastatic and refractory cancers,” Cho said. “Through global clinical trials and commercialization, we aim to not only provide new treatment options but also lead a transformation in the anticancer paradigm.”
Penetrium’s presentation at AACR-NCI-EORTC 2025 is seen as a pivotal moment for reshaping global strategies in cancer therapy, positioning the drug as a potential game-changer in addressing unmet needs in oncology.
Kim Kuk Ju, HEALTH IN NEWS TEAM
press@hinews.co.kr
